Abstract
Bone metastases contribute to morbidity in patients with common cancers, and conventional therapy provides only palliation and can induce systemic side effects. The development of nanostructured delivery systems that combine carriers with bone-targeting molecules can potentially overcome the drawbacks presented by conventional approaches. We have recently developed biodegradable, biocompatible nanoparticles (NP) made of a conjugate between poly (D,Llactide- co-glycolic) acid and alendronate, suitable for systemic administration, and directly targeting the site of tumorinduced osteolysis. Here, we loaded NP with doxorubicin (DXR), and analyzed the in vitro and in vivo activity of the drug encapsulated in the carrier system. After confirming the intracellular uptake of DXR-loaded NP, we evaluated the antitumor effects in a panel of human cell lines, representative for primary or metastatic bone tumors, and in an orthotopic mouse model of breast cancer bone metastases. In vitro, both free DXR and DXR-loaded NP, (58-580 ng/mL) determined a significant dose-dependent growth inhibition of all cell lines. Similarly, both DXR-loaded NP and free DXR reduced the incidence of metastases in mice. Unloaded NP were ineffective, although both DXR-loaded and unloaded NP significantly reduced the osteoclast number at the tumor site (P = 0.014, P = 0.040, respectively), possibly as a consequence of alendronate activity. In summary, NP may act effectively as a delivery system of anticancer drugs to the bone, and deserve further evaluation for the treatment of bone tumors.
Keywords: Bisphosphonates, bone targeting, doxorubicin, drug delivery system, nanoparticles, osteolysis, skeletal metastases.
Current Cancer Drug Targets
Title:Bone-Targeted Doxorubicin-Loaded Nanoparticles as a Tool for the Treatment of Skeletal Metastases
Volume: 10 Issue: 7
Author(s): M. Salerno, E. Cenni, C. Fotia, S. Avnet, D. Granchi, F. Castelli, D. Micieli, R. Pignatello, M. Capulli, N. Rucci, A. Angelucci, A. Del Fattore, A. Teti, N. Zini, A. Giunti and N. Baldini
Affiliation:
Keywords: Bisphosphonates, bone targeting, doxorubicin, drug delivery system, nanoparticles, osteolysis, skeletal metastases.
Abstract: Bone metastases contribute to morbidity in patients with common cancers, and conventional therapy provides only palliation and can induce systemic side effects. The development of nanostructured delivery systems that combine carriers with bone-targeting molecules can potentially overcome the drawbacks presented by conventional approaches. We have recently developed biodegradable, biocompatible nanoparticles (NP) made of a conjugate between poly (D,Llactide- co-glycolic) acid and alendronate, suitable for systemic administration, and directly targeting the site of tumorinduced osteolysis. Here, we loaded NP with doxorubicin (DXR), and analyzed the in vitro and in vivo activity of the drug encapsulated in the carrier system. After confirming the intracellular uptake of DXR-loaded NP, we evaluated the antitumor effects in a panel of human cell lines, representative for primary or metastatic bone tumors, and in an orthotopic mouse model of breast cancer bone metastases. In vitro, both free DXR and DXR-loaded NP, (58-580 ng/mL) determined a significant dose-dependent growth inhibition of all cell lines. Similarly, both DXR-loaded NP and free DXR reduced the incidence of metastases in mice. Unloaded NP were ineffective, although both DXR-loaded and unloaded NP significantly reduced the osteoclast number at the tumor site (P = 0.014, P = 0.040, respectively), possibly as a consequence of alendronate activity. In summary, NP may act effectively as a delivery system of anticancer drugs to the bone, and deserve further evaluation for the treatment of bone tumors.
Export Options
About this article
Cite this article as:
Salerno M., Cenni E., Fotia C., Avnet S., Granchi D., Castelli F., Micieli D., Pignatello R., Capulli M., Rucci N., Angelucci A., Del Fattore A., Teti A., Zini N., Giunti A. and Baldini N., Bone-Targeted Doxorubicin-Loaded Nanoparticles as a Tool for the Treatment of Skeletal Metastases, Current Cancer Drug Targets 2010; 10 (7) . https://dx.doi.org/10.2174/156800910793605767
DOI https://dx.doi.org/10.2174/156800910793605767 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Psychoimmunological Analysis of Cancer Patients: Correlation with the Prognosis
Current Aging Science Celiac Disease: Pathogenesis and Novel Therapeutic Strategies
Endocrine, Metabolic & Immune Disorders - Drug Targets Presenilin and γ -Secretase Activity: A Viable Therapeutic Target for Alzheimers Disease?
Current Signal Transduction Therapy Vitamin D : Autoimmunity and Gender
Current Medicinal Chemistry Comment on the Paper Entitled: “Tumorous Spinal Lesions: Computer Aided Diagnosis and Evaluation Based on CT Data - a Review”
Current Medical Imaging Microenvironmental Interactions in Chronic Lymphocytic Leukemia: Hints for Pathogenesis and Identification of Targets for Rational Therapy
Current Pharmaceutical Design Validated RP-HPLC Method for the Simultaneous Analysis of Gemcitabine and LY-364947 in Liposomal Formulations
Current Drug Targets Use of MHC II Structural Features in the Design of Vaccines for Organ-Specific Autoimmune Diseases
Current Pharmaceutical Design Lymphatic Endothelial Cells, Inflammatory Lymphangiogenesis, and Prospective Players
Current Medicinal Chemistry Mucosal Immunisation: Adjuvants and Delivery Systems
Current Drug Delivery Lack of Association between miR-605 rs2043556 Polymorphism and Overall Cancer Risk: A Meta-analysis of Case-control Studies
MicroRNA From Single- to Multi-Target Drugs in Cancer Therapy: When Aspecificity Becomes an Advantage
Current Medicinal Chemistry Radionuclide Antibody-Conjugates, a Targeted Therapy Towards Cancer
Current Radiopharmaceuticals Cannabis sativa L. Constituents and Their Role in Neuroinflammation
Current Bioactive Compounds <i>Ralstonia Mannitolilytica</i>, an Unusual Pathogen in the Neonatal Intensive Care Unit: A Case of Neonatal Sepsis and Literature Review
Infectious Disorders - Drug Targets Small Non-Coding RNAs as Novel Therapeutics
Current Molecular Medicine Exogenous Hormonal Regulation in Breast Cancer Cells by Phytoestrogens and Endocrine Disruptors
Current Medicinal Chemistry Synthesis of Apoptotic New Quinazolinone-Based Compound and Identification of its Underlying Mitochondrial Signalling Pathway in Breast Cancer Cells
Current Pharmaceutical Design Liver Transporters in Hepatic Drug Disposition: An Update
Current Drug Metabolism Discovery of Hedgehog Antagonists for Cancer Therapy
Current Medicinal Chemistry